ASCO-GU – prostate cancer PARPS move to the front line

ASCO-GU – prostate cancer PARPS move to the front line

Submitted by admin on February 20, 2022 - 11:44am
Source: 
EP Vantage
News Tags: 
prostate cancer
ASCO-GU
PARP inhibitors
Lynparza
Zejula
Rubraca
Talzenna
biomarkers
AstraZeneca
Merck
GSK
JNJ
Clovis Oncology
Headline: 
ASCO-GU – prostate cancer PARPS move to the front line
snippet: 

Lynparza squares off against Zejula while Rubraca and Talzenna wait in the wings, but should first-line use be restricted by biomarkers?

Do Not Allow Advertisers to Use My Personal information